Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 209

1.

Rituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis.

Roubaud-Baudron C, Pagnoux C, Méaux-Ruault N, Grasland A, Zoulim A, LE Guen J, Prud'homme A, Bienvenu B, de Menthon M, Camps S, LE Guern V, Aouba A, Cohen P, Mouthon L, Guillevin L; French Vasculitis Study Group.

J Rheumatol. 2012 Jan;39(1):125-30. doi: 10.3899/jrheum.110143. Epub 2011 Nov 15.

PMID:
22089465
2.

Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: results from a single centre.

Besada E, Koldingsnes W, Nossent JC.

Rheumatology (Oxford). 2013 Nov;52(11):2041-7. doi: 10.1093/rheumatology/ket257. Epub 2013 Aug 11.

PMID:
23934313
3.

B cell strategy to maintain remission in ANCA-associated vasculitides?

Adler S, Villiger PM.

J Rheumatol. 2012 Jan;39(1):4-5. doi: 10.3899/jrheum.111313. No abstract available.

PMID:
22210675
4.

Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations.

Holle JU, Dubrau C, Herlyn K, Heller M, Ambrosch P, Noelle B, Reinhold-Keller E, Gross WL.

Ann Rheum Dis. 2012 Mar;71(3):327-33. doi: 10.1136/ard.2011.153601. Epub 2011 Oct 21.

PMID:
22021864
5.

Treatment of antineutrophil cytoplasmic antibody-associated vasculitis with rituximab.

Cartin-Ceba R, Fervenza FC, Specks U.

Curr Opin Rheumatol. 2012 Jan;24(1):15-23. doi: 10.1097/BOR.0b013e32834d5730. Review.

PMID:
22089095
6.

Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center.

Cartin-Ceba R, Golbin JM, Keogh KA, Peikert T, Sánchez-Menéndez M, Ytterberg SR, Fervenza FC, Specks U.

Arthritis Rheum. 2012 Nov;64(11):3770-8. doi: 10.1002/art.34584.

7.
8.

Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener's). Results of a single-center cohort study on 66 patients.

Calich AL, Puéchal X, Pugnet G, London J, Terrier B, Charles P, Mouthon L, Guillevin L; French Vasculitis Study Group.

J Autoimmun. 2014 May;50:135-41. doi: 10.1016/j.jaut.2014.03.002. Epub 2014 Apr 2.

PMID:
24703438
9.

Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome).

Thiel J, Hässler F, Salzer U, Voll RE, Venhoff N.

Arthritis Res Ther. 2013 Sep 24;15(5):R133. doi: 10.1186/ar4313.

10.

Activity and damage in granulomatosis with polyangiitis.

Yegin EG, Can M, Yilmaz N, Aydin SZ, Yavuz S, Tuglular S, Direskeneli H.

Int J Rheum Dis. 2013 Feb;16(1):61-71. doi: 10.1111/1756-185x.12022. Epub 2013 Feb 2.

PMID:
23441774
11.

Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis.

Alberici F, Smith RM, Jones RB, Roberts DM, Willcocks LC, Chaudhry A, Smith KG, Jayne DR.

Rheumatology (Oxford). 2015 Jul;54(7):1153-60. doi: 10.1093/rheumatology/keu452. Epub 2014 Dec 3.

12.

Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids.

Miloslavsky EM, Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Tchao NK, Ding L, Iklé D, Villareal M, Lim N, Brunetta P, Fervenza FC, Monach PA, Stone JH; Rituximab in ANCA-Associated Vasculitis-Immune Tolerance Network Research Group.

Arthritis Rheumatol. 2015 Jun;67(6):1629-36. doi: 10.1002/art.39104.

13.

Serum immunoglobulin levels and risk factors for hypogammaglobulinaemia during long-term maintenance therapy with rituximab in patients with granulomatosis with polyangiitis.

Besada E, Koldingsnes W, Nossent JC.

Rheumatology (Oxford). 2014 Oct;53(10):1818-24. doi: 10.1093/rheumatology/keu194. Epub 2014 May 15.

PMID:
24831059
14.

Long-term Outcomes of Rituximab Therapy in Ocular Granulomatosis with Polyangiitis: Impact on Localized and Nonlocalized Disease.

Joshi L, Tanna A, McAdoo SP, Medjeral-Thomas N, Taylor SR, Sandhu G, Tarzi RM, Pusey CD, Lightman S.

Ophthalmology. 2015 Jun;122(6):1262-8. doi: 10.1016/j.ophtha.2015.01.016. Epub 2015 Mar 4.

PMID:
25745876
15.

Cyclophosphamide as induction therapy for Wegener's granulomatosis and microscopic polyangiitis.

Langford CA.

Clin Exp Immunol. 2011 May;164 Suppl 1:31-4. doi: 10.1111/j.1365-2249.2011.04364.x. Review.

16.

Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients.

Charles P, Néel A, Tieulié N, Hot A, Pugnet G, Decaux O, Marie I, Khellaf M, Kahn JE, Karras A, Ziza JM, Deligny C, Tchérakian C, Guillevin L; French Vasculitis Study Group.

Rheumatology (Oxford). 2014 Mar;53(3):532-9. doi: 10.1093/rheumatology/ket381. Epub 2013 Nov 26.

PMID:
24282319
17.

Rituximab (MABTHERA) and severe polyangiitis. An option for patients informed of the uncertainties.

[No authors listed]

Prescrire Int. 2015 Jun;24(161):145-8. Review.

PMID:
26436161
18.

Treatment of antineutrophil cytoplasmic antibody-associated vasculitis: update.

Santana AN, Woronik V, Halpern AS, Barbas CS.

J Bras Pneumol. 2011 Nov-Dec;37(6):809-16. Review. English, Portuguese.

19.
20.

Renal transplant in Wegener's granulomatosis compared to microscopic polyangiitis.

Geetha D, Haas M, Kraus ES, Rabb H, Seo P.

J Rheumatol. 2010 Aug 1;37(8):1705-8. doi: 10.3899/jrheum.091202. Epub 2010 Jun 1.

PMID:
20516028

Supplemental Content

Support Center